Page 1

13 September 2021 , Cambridge , UK Abcam plc ( Nasdaq : ABCM ; AIM : ABC ) ( ' Abcam ' , the ' Group ' or the ' Company ' ) , a global leader in the supply of life science research tools , today announces its interim results for the six- and 12 - month periods ended 30 June 2021 ( the ' period ' ) . The Group's accounting reference date has changed from 30 June to 31 December¹ , therefore these interim financial statements report on both a six- and 12 month period . SUMMARY PERFORMANCE ● ● ● ABCAM PLC Interim results for the six- and 12 - month periods ended 30 June 2021 29 % Constant Currency Revenue Growth in H2 as Lab Activity Gradually Recovers and Demand for Abcam In - house Products Increases Revenue Gross profit margin , % Operating profit / ( loss ) Diluted earnings per share ( ' EPS ' ) ( pence ) Net Cash * * Net Cash comprises cash and cash equivalents less borrowings . FINANCIAL HIGHLIGHTS¹ H2 constant exchange rate ( ' CER ' ) revenue growth of 29 % ( 23 % reported ) versus the prior year comparative period . 12 - month CER revenue growth of 18 % ( 14 % reported ) O H2 in - house CER revenue growth ( including CP & L4 ) of 41 % ( 35 % reported ) H2 gross margin increased 250 basis points to 71.4 % , benefiting from the contribution of higher margin in house products . 12 - month gross margin increased to 71.1 % ● ● ● ● ● 12 months to 30 June ● Reported 2021 £ m 297.7 71.1 28.2 7.2 219.9 Adjusted² 2020 2021 2020 £ m £ m £ m 260.0 297.7 260.0 69.3 71.1 69.3 10.5 45.8 44.5 6.0 13.5 16.6 80.9 219.9 80.9 Net cash inflow from operating activities over the 12 - month period of £ 71.9m ( 2020 : £ 63.0m ) , ending the period with a net cash position of £ 219.9m ( 2020 : £ 80.9m ) BUSINESS HIGHLIGHTS Six months to 30 June ( ¹H2¹ ) ³ Reported Adjusted² 2021 £ m 150.2 121.8 71.4 68.9 10.3 ( 16.1 ) 2021 2020 £ m £ m 150.2 121.8 71.4 68.9 19.8 11.1 1.3 ( 6.5 ) 4.8 3.6 219.9 80.9 219.9 80.9 2020 £ m H2 operating profit of £ 10.3m with a 78 % increase in adjusted² operating profit to £ 19.8m , equating to an adjusted operating margin of 13.2 % ( H2 2020 : 9.1 % ) . 12 - month adjusted operating margin of 15.4 % ( 2020 : 17.1 % ) , reflecting continuing investment in the business to support future growth H2 reported diluted EPS of 1.3p ( H2 2020 : -6.5p ) . Adjusted² diluted EPS of 4.8p ( H2 2020 : 3.6p ) reflecting the increase in operating profit offset by a higher deferred tax charge and higher number of shares in issue Customers have gradually returned to labs during the 12 - month period , with global lab activity approaching pre - COVID levels in the largest markets Customer transactional Net Promotor Score ( ' tNPS ' ) up two percentage points year - on - year to +58 , with product satisfaction rates reaching all - time highs for the company In - house product development and sales increased versus 2020 , despite COVID - 19 impact on lab activity ; total in - house revenue in H2 ( including CP & L ) comprised 58 % of total revenue ( H2 2020 : 53 % ) Partnering with biopharma , diagnostic and multiplex platform partners continued to generate current and future sources of growth with the number of commercialized antibodies with these partners rising to more than 800 ( 2020 : 459 ) Progress was made in upgrading of the Group's digital and physical infrastructure to support future growth , including the opening of new and expanded sites in China , Massachusetts , and California Completed secondary US listing on Nasdaq in October 2020 ( in addition to existing AIM listing in the UK ) Expanded Asia , Digital , and Life Science Industry experience within the Board of Directors with the appointments of Bessie Lee , Mark Capone and post period end , Sally Crawford , as Non - Executive Directors Post period end announced agreement to acquire BioVision , Inc , a leading innovator of biochemical and cell - based assays , for cash consideration of $ 340m , with closing expected in October 2021